Xue JS - Search Results

1

Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis.

Liu H, Yang CC, Ma YL, Yang YF, Yan LJ, Ding ZN, Xue JS, Yang LS, Yan YC, Dong ZR, Wang DX, Chen ZQ, Hong JG, Li T. Liu H, et al. Among authors: xue js. Immunotherapy. 2023 Jun;15(9):669-678. doi: 10.2217/imt-2022-0114. Epub 2023 May 4. Immunotherapy. 2023. PMID: 37140011 Review.

2

Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.

Xue JS, Liu H, Meng GX, Ding ZN, Yan LJ, Yao SY, Li HC, Dong ZR, Chen ZQ, Hong JG, Li T. Xue JS, et al. Cancer Immunol Immunother. 2022 Jul;71(7):1633-1644. doi: 10.1007/s00262-021-03103-2. Epub 2021 Nov 8. Cancer Immunol Immunother. 2022. PMID: 34750662 Free PMC article.

3

The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.

Han CL, Meng GX, Ding ZN, Dong ZR, Chen ZQ, Hong JG, Yan LJ, Liu H, Tian BW, Yang LS, Xue JS, Li T. Han CL, et al. Among authors: xue js. Front Immunol. 2022 Feb 8;13:827788. doi: 10.3389/fimmu.2022.827788. eCollection 2022. Front Immunol. 2022. PMID: 35211122 Free PMC article.

4

The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Xue JS, Ding ZN, Meng GX, Yan LJ, Liu H, Li HC, Yao SY, Tian BW, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Xue JS, et al. Front Immunol. 2022 Apr 7;13:872353. doi: 10.3389/fimmu.2022.872353. eCollection 2022. Front Immunol. 2022. PMID: 35464489 Free PMC article.

5

Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.

Ding ZN, Meng GX, Xue JS, Yan LJ, Liu H, Yan YC, Chen ZQ, Hong JG, Wang DX, Dong ZR, Li T. Ding ZN, et al. Among authors: xue js. J Cancer Res Clin Oncol. 2023 May;149(5):1993-2008. doi: 10.1007/s00432-022-04133-8. Epub 2022 Jun 29. J Cancer Res Clin Oncol. 2023. PMID: 35767193 Review.

6

Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.

Tian JC, Liu H, Yan LJ, Ding ZN, Han CL, Tian BW, Tan SY, Dong ZR, Wang DX, Xue JS, Mao XC, Yan YC, Li T. Tian JC, et al. Among authors: xue js. Clin Exp Med. 2023 Oct;23(6):2115-2129. doi: 10.1007/s10238-022-00938-6. Epub 2022 Nov 16. Clin Exp Med. 2023. PMID: 36385419

7

Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.

Tian BW, Yan LJ, Ding ZN, Liu H, Han CL, Meng GX, Xue JS, Dong ZR, Yan YC, Hong JG, Chen ZQ, Wang DX, Li T. Tian BW, et al. Among authors: xue js. Int Immunopharmacol. 2023 Jan;114:109519. doi: 10.1016/j.intimp.2022.109519. Epub 2022 Nov 30. Int Immunopharmacol. 2023. PMID: 36459922 Review.

8

Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.

Tian BW, Yan LJ, Ding ZN, Liu H, Meng GX, Xue JS, Han CL, Dong ZR, Hong JG, Chen ZQ, Wang DX, Li T. Tian BW, et al. Among authors: xue js. Expert Rev Gastroenterol Hepatol. 2023 Jan;17(1):73-83. doi: 10.1080/17474124.2022.2156859. Epub 2022 Dec 12. Expert Rev Gastroenterol Hepatol. 2023. PMID: 36476076

9

Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis.

Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, Xue JS, Dong ZR, Chen ZQ, Hong JG, Wang DX, Han CL, Mao XC, Li T. Tian BW, et al. Among authors: xue js. Immunotherapy. 2022 Dec;14(18):1481-1496. doi: 10.2217/imt-2022-0133. Epub 2022 Dec 20. Immunotherapy. 2022. PMID: 36537255 Review.

10

Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis.

Ding ZN, Meng GX, Xue JS, Liu H, Yang LS, Li RZ, Mao XC, Yan YC, Wang DX, Dong ZR, Li T. Ding ZN, et al. Among authors: xue js. Crit Rev Oncol Hematol. 2023 Apr;184:103940. doi: 10.1016/j.critrevonc.2023.103940. Epub 2023 Feb 15. Crit Rev Oncol Hematol. 2023. PMID: 36805079 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page